Surveyed Neurologists’ Awareness of Merck Serono/EMD Serono’s Oral Cladribine is Double that of Novartis/Mitsubishi Tanabe’s FTY-720 (Gilenia)
WALTHAM, Mass., July 15 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe’s FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS). According to the new report, Brand Perception Series: Physician Segmentation in Multiple Sclerosis, just over one-third of surveyed physicians have heard of FTY-720 (Gilenia) compared with three-quarters of surveyed physicians who are aware of Merck Serono/EMD Serono’s oral cladribine and half of surveyed physicians who are aware of Teva/Active Biotech’s laquinimod.
The majority of surveyed physicians indicate that they will use the surveyed emerging oral agents in relapse/remitting MS patients who have failed therapy with interferon-betas and Teva’s Copaxone. Only a small percentage (10 percent or less) will use the surveyed emerging oral agents in treatment-naive patients. Surveyed physicians report they will most likely prescribe these emerging oral agents for patients who cannot tolerate the side effects of their current therapy or who are unwilling to risk the side effects of Biogen Idec/Elan’s Tysabri.
Thirty percent of physicians surveyed fall into the high-volume, cost-conscious prescriber segment, and value out-of-pocket cost to the patient and reimbursement restrictions more than the other segments in this analysis.
“Among the three physician segments identified in this analysis, the high-volume, cost-conscious prescribers are the most-likely to prescribe FTY-720 (Gilenia) if approved. Survey results indicate the majority of these physicians will reserve prescribing the agent to patients who have failed both interferon-betas and Copaxone, or to those who have failed Tysabri,” said Decision Resources Analyst Cindy Fung, Ph.D. “While FTY-720 may be reserved as a later-line therapy, high-volume, cost-conscious physicians are not as concerned about familiarity with an agent, so they may be more willing to adopt a novel emerging agent, provided it is priced competitively.”
About Brand Perception Series: Physician Segmentation
Brand Perception Series: Physician Segmentation identifies key physician segments to uncover targeted opportunities for current and emerging drug brands. This series offers a fresh look at a competitive drug market by analyzing physician perception of current and emerging drugs using unique physician profiles that will help biopharmaceutical companies understand and size market opportunities.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc. Lisa Osgood Christopher Comfort 781-296-2606 781-296-2597 firstname.lastname@example.org email@example.com
SOURCE Decision Resources